Word: labs
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
...Well, I think that the closer you get to the courses we give and the faculty who teach them, the less atypical we really look. The analogy shouldn’t really be with the humanities courses but with the sciences. A lot of studio courses are like lab courses—they’re intensive, materials-based, results-producing, experimental, high-intensity, work-in-a-group kinds of events… There’s a creative component, but there’s a creative component in science...
...already won. What more was there for me to do?” Nichols says. Study, it seems. “Yeah, I’m a badass motherfucker who studies astrophysics,” Nichols deadpans. He researches at an MIT lab, where his latest project involves shipping mice to Mars. He begins to demonstrate the basic physics governing astronomy using his dinner plate: “Were I to spin it like this”—he stops, interrupting himself, and grabs a fork—“better yet, if I sent this fork...
...lighting technology on a silicon platform could "drive volume economics and mass market," says Mario Paniccia, director of Intel Corp.'s photonics technology lab. Researchers in business and academia are scrambling to create such flexible solar cells because existing solid silicon solar panels are heavy and unwieldy. Flexible, or conformal, solar cells could wrap around surfaces and pack easily for transport. A solar-cell liquid could even be painted...
That's where Keasling comes in. He's focusing his lab's work on producing synthetic artemisinin to drive down the price per dose to pennies. Keasling and his team at Berkeley have already worked out how to extract the genes responsible for making artemisinin and transplanted them into a harmless strain of E. coli. Now they're furiously working those 100-hour weeks to reroute the metabolic traffic in the microbe and produce oodles of artemisinin...
...pioneering as the lab work is the business triangle Keasling has forged linking the university; Amyris Biotechnologies, a company he co-founded; and OneWorld Health, a nonprofit drug company. "This is one of those 'only in Berkeley' stories," says Keasling, laughing. "No one is going to make any profit out of this." Berkeley, which owns the rights to Keasling's technology, has agreed to give it away for nonprofit use. The Amyris staff is working to commercialize the technology. OneWorld Health hopes to be manufacturing the drug within five years...